Kessel, K., Seifert, R., Schäfers, M., Weckesser, M., Schlack, K., Boegemann, M., & Rahbar, K. (2019). Second line chemotherapy and visceral metastases are associated with poor survival in patients with mCRPC receiving (177)Lu-PSMA-617. Theranostics.

Kessel, Katharina, Robert Seifert, Michael Schäfers, Matthias Weckesser, Katrin Schlack, Martin Boegemann, and Kambiz Rahbar. "Second Line Chemotherapy and Visceral Metastases Are Associated With Poor Survival in Patients With MCRPC Receiving (177)Lu-PSMA-617." Theranostics 2019.

Kessel, Katharina, et al. "Second Line Chemotherapy and Visceral Metastases Are Associated With Poor Survival in Patients With MCRPC Receiving (177)Lu-PSMA-617." Theranostics 2019.